
After 2 Years, Immunotherapy Shows Doubled Median Survival Time for Advanced Lung Cancer Patients
A 600-patient randomized clinical trial supports pembrolizumab and chemotherapy as a first-line treatment
May 31, 2019 2:24 PM
A 600-patient randomized clinical trial supports pembrolizumab and chemotherapy as a first-line treatment
A new tool that takes into account personalized risks and benefits, and allows for a range of patient preferences, will help clinicians decide whom to screen for lung cancer.